Toronto, Canada, June 20th 2014: Tissue Regeneration Therapeutics Inc. (TRT) today
announced that pre-clinical research utilizing its patented mesenchymal stromal/stem cell
(MSC) technology TXP, was presented at the International Society for Stem Cell Research
conference in Vancouver June 19th.

Dr. Lorena R. Braid of the Defence Research and Development Canada, Suffield Research
Centre, Bio-Threat Defence Section, presented significant pre-clinical data demonstrating
that TXP cells transfected to release viral antibodies over a sustained period provided
protection from lethal levels of virus exposure in an animal model, demonstrating its
potential as a highly effective prophylactic biomedical countermeasure. The presented data
is another important milestone in the advancement of the TRT platform technology into a
broad range of defense and civilian therapeutic applications.

TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology
and its TXP family of cell therapy products. TRT has discovered the world’s richest source
of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-
inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC
platform technology are founded on the highly enriched source of these important cells
compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at
harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal
cells within the harvested population, their increased biological potential compared to cells
derived from adult tissues and their inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and its TXP cell therapy products. TRT is the only company in the
world to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities to
collaborating partner companies in the regenerative medicine, defense, and family banking
sectors. Additional information is available at https://www.verypowerfulbiology.com